Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients With Idiopathic Pulmonary Fibrosis

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients With Idiopathic Pulmonary Fibrosis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LTI 03 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms RENEW
  • Sponsors Rein Therapeutics

Most Recent Events

  • 19 Aug 2025 According to a Rein Therapeutics media release, Rein is actively working with clinical sites in the UK to begin patient recruitment soon.
  • 19 Aug 2025 According to a Rein Therapeutics media release, company announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 RENEW clinical trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
  • 14 Aug 2025 According to a Rein Therapeutics media release, Dr. Windsor will give an overview of this trial assessing safety, tolerability, and focus on lung function as a key outcome and will discuss trial design, strategies around patient recruitment, and how company is working to make the study feasible and relevant in a fast-changing treatment landscape at the IPF Summit 2025, taking place Aug 19-21, 2025, in Boston, MA and will also discuss the same information in workshop at 9:30 am on Thursday.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top